E.i. Dupont De Nemours and Company

Invista North America S.a.r.l.

Cytokinetics, Inc.

Amgen Inc.

Alan Martin Allgeier

Sourav Kumar Sengupta

Joachim C Ritter

Wathudura Indika Namal De Silva

Carl Andrew Menning

Christian Peter Lenges

Ekaterini Korovessi

David Richard Corbin

Sheng Cui

Karthik Nagapudi

Henry Morrison

Steven Mennen

Charles Bernard

Neil Fred Langille

Karl Bennett Hansen

Shawn D Walker

Robert John Barsotti

Laura Ann Lewin

Patrick Henry Corcoran

Stefan Reinartz

Torren Ryan Carlson

Jacqueline C S Woo

Bradley Paul Morgan

Alex R Muci

Julio Cesar Medina

Helen S M Lu

John Joseph Ostermaier

Theodore Augur Koch

Christina S Stauffer

Jiwen Liu

Joseph F Payack

Yingcai Wang

Kalindi Dogra

H David Rosenfeld

An-Rong Li

David P Higley

Domenic J Barsotti

Thomas P Gannett

Yongli Su

Mark Jay Harper

Thomas Storz

Jerry A Murry

Mark Grillo

Joseph E Murphy

Jacqueline E Milne

Kelley Moran Whittle

Janan Jona

Jacqueline Woo

Jacqueline Milne

Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Salt of omecamtiv mecarbil and process for preparing salt

Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use. Omecamtiv mecarbil (AMG 423, CK-1827452), having the structure: 

Disclosed herein are processes for preparing an &#x3b1;,&#x3c9;-C-diol, wherein n is 5 or greater, from a feedstock comprising a Coxygenate. In one embodiment, the process comprises contacting the feedstock with hydrogen gas in the presence of a catalyst comprising Pt, Cu, Ni, Pd, Pt, Rh, Ir, Ru, or Fe on a WOor WOsupport. In one embodiment, the process comprises contacting the feedstock with hydrogen in the presence of a catalyst comprising a metal M1 and a metal M2 or an oxide of M2, and optionally a support. In one embodiment, M1 is Pd, Pt, or Ir; and M2 is Mo, W, V, Mn, Re, Zr, Ni, Cu, Zn, Cr, Ge, Sn, Ti, Au, or Co. The Coxygenate may be obtained from a biorenewable resource.

Production of alpha, omega-diols

Disclosed are processes for preparing 1,6-hexanediol and synthetic intermediates useful in the production of 1,6-hexanediol from renewable biosources. In one embodiment, a process comprises contacting levoglucosenone with hydrogen in the presence of a first hydrogenation catalyst at a first temperature to form product mixture (I); and heating product mixture (I) in the presence of hydrogen and a second hydrogenation catalyst at a second temperature to form product mixture (II) which comprises 1,6-hexanediol.

Process for preparing 1, 6-hexanediol

Disclosed are processes for preparing 1,6-hexanediol from levoglucosenone. In one embodiment, the process comprises contacting levoglucosenone with hydrogen in the presence of a hydrogenation catalyst comprising palladium, platinum/tungsten, nickel/tungsten, rhodium/rhenium, or mixtures thereof at a first temperature between about 50&#xb0; C. and 100&#xb0; C. and at a first reaction pressure between about 50 psi and 2000 psi for a first reaction period, and at a second temperature between about 120&#xb0; C. and 250&#xb0; C. and at a second pressure between about 500 psi and 2000 psi for a second reaction period to form a product mixture comprising 1,6-hexanediol, wherein the first reaction period is the amount of time in which the levoglucosenone has a conversion of at least about 95%.

Disclosed are processes for preparing 1,6-hexanediol from levoglucosenone. In one embodiment, the process comprises contacting levoglucosenone with hydrogen in the presence of a hydrogenation catalyst comprising palladium, platinum/tungsten, nickel/tungsten, rhodium/rhenium, or mixtures thereof at a first temperature between about 50&#xb0; C. and 100&#xb0; C. and at a first reaction pressure between about 50 psi and 2000 psi for a first reaction period, and at a second temperature between about 120&#xb0; C. and 250&#xb0; C. and at a second pressure between about 500 psi and 2000 psi for a second reaction period to form a product mixture comprising 1,6-hexanediol, wherein the first reaction period is the amount of time in which the levoglucosenone has a conversion of at least about 95%. In one embodiment, the 1,6-hexanediol is converted to 1,6-diaminohexane.

Process for preparing 1,6-hexanediol

Disclosed are processes for preparing 1,6-hexanediol and synthetic intermediates useful in the production of 1,6-hexanediol from renewable biosources. In one embodiment, a process comprises contacting levoglucosenone with hydrogen in the presence of a first hydrogenation catalyst at a first temperature to form product mixture (I); and heating product mixture (I) in the presence of hydrogen and a second hydrogenation catalyst at a second temperature to form product mixture (II) which comprises 1,6-hexanediol. In one embodiment, the 1,6-hexanediol is converted to 1,6-diaminohexane.

Disclosed herein are processes for preparing an &#x3b1;,&#x3c9;-C-diol, wherein n is 5 or greater, from a feedstock comprising a Coxygenate. In some embodiments, the process comprises contacting the feedstock with hydrogen gas in the presence of a catalyst comprising metals M1, M2, and M3 and optionally a support, wherein: M1 is Mn, Cr, V, or Ti; M2 is Ni, Co, or Fe; and M3 is Cu, Ag, Pt, Pd or Au; or M1 is Pt or Rh; M2 is Cu, Ni or Pd; and M3 is Mo, Re or W. The Coxygenate may be obtained from a biorenewable resource.

Disclosed herein are processes for preparing an &#x3b1;,&#x3c9;-C-diol, wherein n is 5 or greater, from a feedstock comprising a Coxygenate. In one embodiment, the process comprises contacting the feedstock with hydrogen gas in the presence of a catalyst comprising Cu, a Cu oxide, or mixtures thereof; a heteropoly acid component comprising H[P(WO)], H[Si(WO)], H[P(MoO)], H[Si(MoO)], CsH[P(WO)], CsH[Si(WO)], or mixtures thereof; optionally a second metal component comprising Cr, a Cr oxide, Ni, a Ni oxide, Mn, a Mn oxide, Fe, an Fe oxide, Co, a Co oxide, Mo, a Mo oxide, W, a W oxide, Re, a Re oxide, Zn, or a Zn oxide, Ag, a Ag oxide, SiO, or AlO; optionally at least one promoter comprising Na, K, Mg, Rb, Cs, Ca, Sr, Ba, Ce, or mixtures thereof; and optionally a support.

Production of &#x3b1;,&#x3c9;-diols

Disclosed herein are processes for preparing an &#x3b1;,&#x3c9;-C-diol, wherein n is 5 or greater, from a feedstock comprising a Coxygenate. In one embodiment, the process comprises contacting the feedstock with hydrogen gas in the presence of a catalyst comprising a first metal component comprising Ni, Ir, Pt, Rh, Ru, Pd, Fe, Ag, or Au; a heteropoly acid component comprising H[P(WO)], H[Si(WO)], H[P(MoO)], H[Si(MoO)], CsH[P(WO)]CsH[Si(WO)], or mixtures thereof; optionally a second metal component comprising Cr, a Cr oxide, Ni, a Ni oxide, Fe, a Fe oxide, Co, a Co oxide, Mn, a Mn oxide, Mo, a Mo oxide, W, a W oxide, Re, a Re oxide, Zn, a Zn oxide, SiO, or AlO; optionally at least one promoter comprising Na, K, Mg, Rb, Cs, Ca, Sr, Ba, Ce, or mixtures thereof; and optionally a support. In one embodiment, the optional support is present in the catalyst and comprises WO, SiO, AlO, carbon, TiO, ZrO, SiO&#x2014;AlO, montmorillonite, SiO&#x2014;TiO, tungstated ZrO, zeolites, VO, MoO, or mixtures thereof. The Coxygenate may be obtained from a biorenewable resource.

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.

Phenyl acetic acid derivatives

Growing community of inventors

Wilmington, DE, United States of America

Alan Martin Allgeier